Woo, W A <br/><br/>
Switching biological agents for psoriasis in secondary care: a single-centre, retrospective, open-label study.  [electronic resource] 

 -  The British journal of dermatology  Apr 2014 
 - 989-90 p.  digital 
<br/><br/> Publication Type: Letter 
<br/><br/><label>ISSN: </label>1365-2133 
<br/><br/><label>Standard No.: </label>10.1111/bjd.12764  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Biological Factors--therapeutic use<br/>Dermatologic Agents--therapeutic use<br/>Drug Substitution<br/>Etanercept<br/>Female<br/>Humans<br/>Immunoglobulin G--therapeutic use<br/>Infliximab<br/>Male<br/>Middle Aged<br/>Psoriasis--drug therapy<br/>Receptors, Tumor Necrosis Factor--therapeutic use<br/>Retrospective Studies<br/>Secondary Care--methods<br/>Ustekinumab